D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal Article
The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis.
Edith A. Perez,David R. Gandara +1 more
Journal ArticleDOI
Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.
Jonathan W. Riess,Susan Groshen,Karen L. Reckamp,Heather A. Wakelee,Geoffrey R. Oxnard,Sukhmani K. Padda,Marianna Koczywas,Zofia Piotrowska,Lynette M. Sholl,Cloud P. Paweletz,Christie J. Lau,Jill M. Kolesar,Philip C. Mack,Jeffrey A. Moscow,Pasi A. Jänne,Primo N. Lara,Edward M. Newman,David R. Gandara +17 more
TL;DR: Osi (3rd gen EGFR TKI) has robust activity in 1st line EGFR mutant NSCLC and TKI resistant T790MposNSCLC but progressive disease occurs and outcomes with Osi alone are poor in these studies.
Journal ArticleDOI
O-187 ZD1839 (iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG SO126
Howard West,Wilbur A. Franklin,Paul H. Gumerlock,Ralph B. Vance,Derick H Lau,Kari Chansky,John Crowley,Jason McCoy,David R. Gandara +8 more
Journal ArticleDOI
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
Stephen K. Williamson,Sheryl McCoy,David R. Gandara,Shaker R. Dakhil,Kathleen J. Yost,Jorge C. Paradelo,James N. Atkins,Charles D. Blanke,James L. Abbruzzese +8 more
TL;DR: The length of survival suggests that this combination of gemcitabine and irinotecan has benefit similar to platinum containing regimens, however, the toxicity is substantial and is unlikely to prove superior to platinumcontaining regimens.
Journal ArticleDOI
Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.
TL;DR: In patients with SCLC, age less than 50 years was an independent predictor of improved CSS, and these results have potential clinical applications.